Global Cardiometabolic Drugs Industry The Global Cardiometabolic Drugs Industry is on the brink of a remarkable surge, projected to reach a substantial US$ 50 billion by 2021, and further skyrocketing to exceed US$ 70 billion by 2032, according to the latest market analysis. These insights, driven by a Compound Annu.